title: Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database.
abstract: OBJECTIVE
  To investigate putative associations of reports of memory disorders and suspected drugs.
  
  
  METHODS
  We used the case/noncase method in the French PharmacoVigilance Database (FPVD). Cases were reports of memory loss in the FPVD between January 2000 and December 2009. Noncases were all other reports during the same period. To assess the association between memory impairment and drug intake, we calculated an odds ratio with its 95% confidence interval.
  
  
  RESULTS
  Among the 188,284 adverse drug reactions recorded, we identified 519 cases of memory loss. The sex ratio was 0.6 and the median age was 54 years (range 4-93). The maximal number of cases occurred between 40-49 and 50-59 years. Evolution was favourable in 63% of the cases. We found significant odds ratios for benzodiazepines (alprazolam, bromazepam, prazepam, clonazepam etc.), benzodiazepine-like hypnotics (zolpidem and zopiclone), antidepressants (fluoxetine, paroxetine and venlafaxine), analgesics (morphine, nefopam and tramadol), anticonvulsants (topiramate, pregabalin, levetiracetam etc.), antipsychotics (aripiprazole and lithium) and other drugs, such as trihexyphenidyl, ciclosporin and isotretinoin.
  
  
  CONCLUSIONS
  Our study confirmed an association between memory disorders and some drugs, such as benzodiazepines and anticonvulsants. However, other drugs, such as benzodiazepine-like hypnotics, newer anticonvulsants, serotonin reuptake inhibitor antidepressants, isotretinoin and ciclosporin were significantly associated with memory disorders, although this was not described or poorly described in the literature. Taking account of the limits of this study in the FPVD (under-reporting, notoriety bias etc.), the case/noncase method allows assessment and detection of associations between exposure to drugs and a specific adverse drug reaction, such as memory disorders, and could thus generate signals and orientate us to further prospective studies to confirm such associations.
authors.affiliation: CHU de Poitiers, Service de Pharmacologie clinique et Vigilances, Centre Régional de PharmacoVigilance et de Renseignement sur les Médicaments, Poitiers, France. francois.chavant@chu-poitiers.fr
authors.forename: Francois
authors.initials: F
authors.lastname: Chavant
authors.forename: Sylvie
authors.initials: S
authors.lastname: Favrelière
authors.forename: Claire
authors.initials: C
authors.lastname: Lafay-Chebassier
authors.forename: Caroline
authors.initials: C
authors.lastname: Plazanet
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Pérault-Pochat
mesh_terms: D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data*; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D016208:Databases, Factual / Q000706:statistics & numerical data; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000139:chemically induced* / Q000453:epidemiology; D008875:Middle Aged; D016017:Odds Ratio; D012737:Sex Factors; D055815:Young Adult